| Literature DB >> 34928264 |
Chiara Offi1, Roberto Maria Romano1, Angelo Cangiano1, Marcello Filograna Pignatelli1, Giancarlo Candela1, Giovanni Docimo1.
Abstract
OBJECTIVE: Thyroid nodules with indeterminate cytology represent 20% of all thyroid nodules. Inflammation plays an important role in cancer. Lymphocyte-to-monocyte ratio (LMR), neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are independent prognostic scores in numerous cancers, although no study has documented their role in cytology indeterminate nodules. The aim of this study is to evaluate the role of LMR, NLR and PLR values as predictors of malignancy in patients with cytology indeterminate nodules.Entities:
Keywords: indeterminate thyroid nodule; lymphocyte-to-monocyte ratio; neutrophil-to-lymphocyte ratio; platelet-to-lymphocyte ratio; thyroid cancer
Mesh:
Year: 2021 PMID: 34928264 PMCID: PMC8686799 DOI: 10.14639/0392-100X-N1515
Source DB: PubMed Journal: Acta Otorhinolaryngol Ital ISSN: 0392-100X Impact factor: 2.124
Patient demographic and clinicopathological data.
| Characteristics | Population | Group A | Group B | |
|---|---|---|---|---|
|
| 298 | 59 (19.79) | 239 (80.21) | < 0.001 |
|
| ||||
| Male | 63 (21.14) | 12 (20.33) | 51 (21.33) | 0.866 |
| Female | 235 (78.46) | 47 (79.66) | 188 (78.66) | |
|
| 50.69 (± 14.73) | 49.08 (± 12.88) | 51.09 (± 15.15) | 0.370 |
| I (%) | 56 (18.8) | 56 (94.91) | NA | NA |
| II (%) | 3(1) | 3 (5.09) | ||
|
| 1.54 (±0.9) | NA | NA | |
|
| ||||
| Right | 24 (8.05) | 24 (40.7) | NA | NA |
| Left | 35 (11.75) | 35 (59.3) | ||
|
| 298 | 59 (19.79) | 239 (80.21) | < 0.001 |
SD: standard deviation; NA: not applicable.
Figure 1.Flow-chart of eligible patients.
Baseline haematological values.
| Blood values | Population | Group A | Group B | |
|---|---|---|---|---|
| Mean white blood cell (± SD) | 7.30 (± 1.87) | 6.81 (± 1.66) | 7.41 (± 1.9) | 0.02 |
| Mean neutrophils (± SD) | 4.61 (± 1.54) | 4.32 (± 1.5) | 4.68 (± 1.54) | 0.62 |
| Mean lymphocytes (± SD) | 2.07 (± 0.55) | 1.78 (± 0.36) | 2.14 (± 0.57) | < 0.001 |
| Mean monocytes (± SD) | 0.41 (± 0.13) | 0.50 (± 0.12) | 0.39 (± 0.12) | < 0.001 |
| Mean eosinophils (± SD) | 0.15 (± 0.1) | 0.14 (± 0.10) | 0.15 (± 0.11) | 0.289 |
| Mean basophils (± SD) | 0.04 (± 0.02) | 0.04 (± 0.03) | 0.38 (± 0.02) | 0.784 |
| Mean platelets (± SD) | 260.370 (± 63.2) | 254.800 (± 53.49) | 262.426 (± 65.15) | 0.439 |
| Mean LMR (± SD) | 5.61 (± 2.82) | 3.46 (± 0.64) | 6.10 (± 2.94) | < 0.001 |
| Mean NLR (± SD) | 2.31 (± 0.82) | 2.26 (± 0.80) | 2.49 (± 0.87) | 0.58 |
| Mean PLR | 132.878 (± 43.02) | 129.674 (± 43.42) | 145.857 (± 39.13) | 0.003 |
SD: standard deviation; LMR: lymphocyte-to-monocyte ratio; NLR: neutrophil-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio
*x1000.
Univariate and multivariate analysis evaluating the odds of PTC.
| Univariate OR (95% CI) | Adjusted OR[ | |||
|---|---|---|---|---|
| NLR | 0.712 (0.440-1.152) | 0.166 | 0.513 (0.61-4.326) | 0.539 |
| LMR | 0.130 (0.071-0.238) | < 0.001 | 0.216 (0.028-1.671) | 0.142 |
| PLR | 1.001 (0.991-1.012) | 0.825 | 1.012 (0.969-1.057) | 0.590 |
| Cancer when LMR < 4.09 | 26.058 (11.898-57.072) | < 0.001 | 2.960 (0.787-11.136) | 0.109 |
Adjusted for full blood count values (OR: odds ratio; CI: confidential interval; LMR: lymphocytes-to-monocytes ratio; NLR: neutrophil-to-lymphocytes ratio; PLR: platelet-to-lymphocytes ratio.
Figure 3.ROC curves of PLR (cut-off value 121.665, AUC 0.623 ± 0.39, sensitivity 69.5% and specificity of 48.1%).
Figure 4.ROC curves of NLR (AUC 0.58 ± 0.4, no valid cut-off value found).